医疗器械公司Globus Medical Inc.(纽约证券交易所代码:GMED)期周一股价盘前大涨12.46%,主因其第三季度业绩和全年预期均超出市场预期。
财报显示,Globus Medical第三季度调整后每股收益为0.83美元,高于分析师预期的0.65美元。公司第三季度收入达到6.257亿美元,同比增长63.1%,也超过了分析师预测的6.0471亿美元。
公司称,第三季度业绩出色主要得益于近期收购医疗器械公司NuVasive。公司旗下的脊柱产品销售和使能技术产品及服务销量的强劲表现也为业绩增长贡献重要力量,尤其是在国际市场,净销售额同比增长达74.8%。
凭借第三季度的出色表现,Globus Medical上调了2024财年的每股收益指引至2.90-3.00美元,高于此前指引2.80-2.90美元,也超过了华尔街2.85美元的共识预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.